For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| License revenue | 0 | 0 | 0 | 0 |
| Research and development | 7,003,000 | 6,296,000 | 7,437,000 | 9,319,000 |
| General and administrative | 4,256,000 | 3,966,000 | 3,541,000 | 4,101,000 |
| Impairment of right-of-use assets and property and equipment | - | 7,348,000 | - | - |
| Total operating expenses | 11,259,000 | 17,610,000 | 10,978,000 | 13,420,000 |
| Income (gain) from operations | -11,259,000 | -17,610,000 | -10,978,000 | -13,420,000 |
| Interest income | 1,023,000 | 1,184,000 | 1,164,000 | 1,118,000 |
| Other income (expense) | 1,200,000 | 1,310,000 | 1,316,000 | 1,741,000 |
| Total other income (expense), net | 2,223,000 | 2,494,000 | 2,480,000 | 2,859,000 |
| Net income (gain) | -9,036,000 | -15,116,000 | -8,498,000 | -10,561,000 |
| Unrealized loss (gain) on investments, net | -137,000 | -41,000 | 167,000 | -6,000 |
| Comprehensive income (gain) | -9,173,000 | -15,157,000 | -8,331,000 | -10,567,000 |
| Basic EPS | -0.16 | -0.266 | -0.15 | -0.19 |
| Diluted EPS | -0.16 | -0.258 | -0.15 | -0.19 |
| Basic Average Shares | 57,233,413 | 57,076,093 | 56,929,103 | 56,803,450 |
| Diluted Average Shares | 57,233,413 | 58,845,332 | 56,929,103 | 56,803,450 |
Black Diamond Therapeutics, Inc. (BDTX)
Black Diamond Therapeutics, Inc. (BDTX)